Summary & Overview

CPT 84066: Prostatic Acid Portion of Total Acid Phosphatase, Serum

CPT code 84066 represents a laboratory assay measuring the prostatic acid portion of total acid phosphatase, typically performed on a serum specimen. The test is clinically relevant for assessing prostate-derived enzyme activity and has implications for evaluation of prostate disease and monitoring. Nationally, laboratory performance and coverage for prostate-related enzyme assays contribute to diagnostic pathways in urology and oncology care.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for the assay, common sites of service, and an outline of payer coverage considerations. The publication summarizes benchmarking baselines where available, highlights coding and billing practice points, and reviews relevant policy and reimbursement updates that affect laboratory billing for prostate enzyme testing.

This summary provides clinicians, laboratory managers, and billing professionals with practical background on the test's purpose and service setting, plus a roadmap of the materials in the full publication covering coverage policies, payment benchmarks, and coding considerations for CPT code 84066.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare84066CPTprostatic acid phosphataselaboratoryserum testprostate markerclinical chemistryurology

Billing Code Overview

CPT code 84066 measures the prostatic acid portion of total acid phosphatase, most commonly performed on a serum specimen. The test quantifies enzyme activity produced primarily by the prostate gland in males and is used in clinical evaluation related to prostate function and disease.

Service Type: Clinical laboratory test — specialty chemistry / prostate tumor marker

Typical Site of Service: Clinical laboratory or hospital outpatient laboratory, with specimen collection most commonly in an ambulatory phlebotomy setting or hospital laboratory.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult male referred for serum prostatic acid phosphatase (PAP) testing to assist in evaluation or monitoring of prostate disease. A common scenario is a urology clinic visit for a patient with known prostate cancer, rising prostate-specific antigen (PSA) levels after treatment, or symptoms suggesting advanced prostate disease. The clinical workflow: a provider orders CPT 84066 when microsomal prostatic acid phosphatase measurement is needed; a phlebotomy technician collects a serum specimen in the outpatient laboratory or hospital draw station (typical sites: hospital lab, independent clinical laboratory, ambulatory surgery center, or outpatient clinic). The specimen is processed and analyzed by a clinical laboratory scientist or lab analyst; results are reported in the electronic medical record and reviewed by the ordering urologist or oncologist for disease staging, treatment response assessment, or surveillance of recurrence.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	When only the professional interpretation or report is billed separately from the technical component for lab-based tests with split billing.
`TC`	Technical component	When only the technical component (laboratory processing, equipment, specimen handling) is billed.
`90`	Reference (outside) laboratory	When the test is performed by an outside (reference) laboratory and billed by the performing lab.
`91`	Repeat clinical diagnostic laboratory test	When the same lab test is repeated on the same day to obtain multiple results (note: `91` is not in the provided list; not used).
`59`	Distinct procedural service	Not listed in input; therefore not used.
`52`	Reduced services	When the laboratory performs a reduced or partial version of the test (rare for standardized assays).
`53`	Discontinued procedure	If specimen collection or testing was started but discontinued for clinical reasons.
`90`	Reference laboratory billing	See above; used by performing outside lab (duplicate entry avoided).
`11`	Normal processing	When service is provided as expected without unusual circumstances (often default reporting).
`22`	Increased procedural services	When the lab incurs substantially greater work than typical (rare for automated assays).
`62`	Two surgeons/clinicians	Not applicable to laboratory testing but included by policy lists; not typically used for `CPT 84066`.

Taxonomy Code	Specialty	Notes
207RH0000X	Urology	Urologists commonly order and interpret PAP testing for prostate disease.
207L00000X	Diagnostic Radiology	Radiologists are less commonly involved but may coordinate staging; included for multidisciplinary care.
362A00000X	Clinical Pathology (Laboratory)	Clinical laboratory specialists and pathologists perform, validate, and report the assay.
207K00000X	Oncology	Medical oncologists manage prostate cancer therapy and interpret PAP trends.
208000000X	Family Medicine	Primary care clinicians may order initial testing or surveillance in coordination with specialists.

Note: From the provided modifier list, the table emphasizes the most clinically relevant modifiers for laboratory billing. Only the most applicable provider taxonomies are shown based on typical ordering and performing clinicians.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C61`	Malignant neoplasm of prostate	Primary indication for PAP testing for staging, prognosis, and monitoring treatment response or recurrence.
`N40`	Benign prostatic hyperplasia	May prompt evaluation of prostate biomarkers when symptoms overlap or to help differentiate causes.
`R97.2`	Elevated prostate specific antigen [PSA]	Often accompanies or prompts further biomarker testing, including PAP, during surveillance.
`R31.9`	Hematuria, unspecified	Hematuria evaluation can include prostate testing when urologic sources are suspected.
`Z08`	Encounter for follow-up examination after completed treatment for malignant neoplasm	Used for surveillance visits where PAP may be measured to monitor for recurrence.
`C79.82`	Secondary malignant neoplasm of genital organs	Indicates metastatic prostate cancer where PAP levels may assist in assessing disease burden.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81002`	Urinalysis, non-automated, without microscopy	Performed in urology or outpatient visits when assessing urinary symptoms alongside prostate testing.
`80053`	Comprehensive metabolic panel; 14 tests	Common adjunct lab panel ordered with serum assays to assess baseline metabolic status before cancer therapy.
`84153`	Prostate specific antigen (PSA); total	Frequently ordered alongside `CPT 84066` for screening, monitoring, and correlation with PAP in prostate disease management.
`87070`	Culture, bacterial; urine, colony count	Ordered when urinary tract infection is a concurrent concern in symptomatic patients undergoing prostate evaluation.
`86303`	Immunoassay for analyte other than infectious agent; quantitative, each	General category for quantitative immunoassays; similar lab workflows and billing considerations to `CPT 84066`.